drug · small molecule
neladalkib
pre_registrationupdated 6mo agoby $NUVL Nuvalent, Inc.🔗 ChEMBL
community read0 votes
Small molecule drug with a maximum clinical stage of Phase 1 2, with 1 investigational indication.
indications
indications
NSCLC
all catalysts(0)
nothing on the calendar yet
Trials studying neladalkib
News(9)
- FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSKThe FDA had several issues with ivonescimab, according to the letter. Elsewhere, Sellas shares rocketed on results for a leukemia vaccine and Biogen and Lilly struck up new R&D pacts.biopharma_dive · 19h ago
- GSK nabs FDA greenlight for second lung cancer asset from Nuvalent buyNelkarmi is one of two bounties from GSK’s $10.6 billion acquisition of Nuvalent Bio—the other being the ROS1 inhibitor zidesamtinib, which won FDA approval earlier this year as Jideytro.biospace · 20h ago
- GSK’s Nuvalent buyout delivers again as FDA clears Nelkarmi for lung cancerGSK has secured a US accelerated approval for its oral lung cancer drug neladalkib, one of two assets at the heart of its $10.6 billion purchase of oncology drugmaker Nuvalent earlier this ...endpoints · 1d ago
- ESMO: GSK cancer R&D chief says mo-rez data ‘reinforces our belief’ in ADC as phase 3 push ramps upGSK’s cancer R&D chief has suggested the latest slice of early-stage data on its B7-H4-directed antibody-drug conjugate (ADC) has “reinforce[d] our belief in the asset,” as the therapy races throug…fiercebiotech · 28d ago
- Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology pushBetter-than-expected sales helped Biogen regain the support of investors, while AstraZeneca and GSK worked to convince Wall Street that they can hit ambitious revenue targets.biopharma_dive · 3mo ago
- GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyardGSK has unveiled an ambitious three-year plan to divert resources to its late-stage R&D programs and shift its research headquarters—but CEO Luke Miels is being tight-lipped about the extent of any…fiercebiotech · 3mo ago
- GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drugJideytro is GSK’s first approved product for lung cancer. With its takeover of Nuvalent Bio last month and a deal with Hansoh Pharmaceutical in 2023, the pharma now has several other lung cancer as…biospace · 3mo ago
- GSK lung cancer drug gets speedy approval following $10.6B dealThe clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British drugmaker into oncology.biopharma_dive · 3mo ago
- GSK boosts cancer pipeline with $11B Nuvalent buyoutThe British drugmaker's third acquisition this year gives it two experimental lung cancer drugs under FDA review that it hopes will support a franchise.biopharma_dive · 5mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that